A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
- Conditions
- Asthma
- Interventions
- Drug: 610 30mg groupDrug: 610 100mg groupDrug: 610 300mg groupOther: Placebo 30mg groupOther: Placebo 100mg groupOther: Placebo 300mg group
- Registration Number
- NCT05584306
- Brief Summary
This study will assess the safety, tolerability, pharmacokinetics and preliminary efficacy of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.
- Detailed Description
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of 610 in adults with severe eosinophilic asthma. Plan to recruit 24 subjects, and the subjects divided into 3 groups: 610 30mg group，100mg group, 610 300mg group，8 subjects in each dose group, of which 6 received the trial drug and 2 received placebo. The study is divided into screening period of 2 weeks, treatment period of 32 weeks and follow-up period of 12 weeks.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 24
- Diagnosed with asthma for ≥12 months
- Within 3 months before screening, treatment with medium to high dose inhaled corticosteroid（ICS，inhaled fluticasone at a dosage of at least 500 μg, or equivalent, daily.）and at least one other additional controller medication, such as long-acting β₂ receptor agonist (LABA), leukotriene receptor antagonist (LTRA), theophylline, long-acting Anticholinergic drugs (LAMA), etc. Those medicine must be stable for ≥ 28 days prior to screening and baseline and must continue without dosage changes throughout the study
- In the past 12 months prior to screening， at least one time asthma exacerbations history
- Pre-bronchodilator FEV1 <80% predicted value
- Asthma-related blood eosinophils ≥ 150 cells/μL within 3 months before administration
- With clinically important lung diseases other than asthma that may affect safety or efficacy and evaluated by investigator. This includes lung infection, chronic obstructive pulmonary disease, bronchiectasis, hypersensitivity pneumonitis, pulmonary fibrosis, Allergic bronchopulmonary aspergillosis, etc.
- With other conditions that could lead to elevated eosinophils such as hypereosinophilic syndromes, eosinophilic granulomatosis with polyangiitis (EGPA), or eosinophilic esophagitis
- In past 12 months prior to screening，patients has done bronchial thermoplasty or radiotherapy or plan to do it during of the trial
- with severe cardiac disease or uncontrolled or severe cardiac arrhythmia
- poorly controlled systemic disease
- Active infection 7 day before screening
- Parasitic infection within 6 months before screening
- At screening, HBsAg or HCV Ab or HIV Ab or TP Ab positive; HBsAg or HCV Ab positive need to be further tested of HBV DNA titer detection or HCV RNA detection (More than normal value range needs to be excluded)
- Subjects who have received any monoclonal antibody treatment of anti IL-4Ror anti-IL-5/5R
- Vaccination history with live vaccines (including live attenuated vaccines) within 4 weeks before screening, or plan to receive during of the trial
- Participated in any interventional clinical trial and received intervention within 3 months before screening
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 610 30mg group 610 30mg group 610 30 mg administered subcutaneously every 4 weeks 610 100mg group 610 100mg group 610 100 mg administered subcutaneously every 4 weeks 610 300mg group 610 300mg group 610 300mg administered subcutaneously every 4 weeks Placebo 30mg group Placebo 30mg group placebo subcutaneous (SC) Q4W，8 times Placebo 100mg group Placebo 100mg group placebo subcutaneous (SC) Q4W，8 times Placebo 300mg group Placebo 300mg group placebo subcutaneous (SC) Q4W，8 times
- Primary Outcome Measures
Name Time Method Adverse events(AEs) From Day 0 to Day 308 The incidence and severity of AEs, including SAEs, as well as clinical symptoms, and any abnormalities of vital signs, physical examinations#electrocardiogram#laboratory tests and, etc.
- Secondary Outcome Measures
Name Time Method Pharmacokinetics-Tmax From Day 0 to Day 308 Time to Cmax of 610
Anti-drug-antibody From Day 0 to Day 308 The percentage of subjects with positive ADA titers over time for 610
Percentage change from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1) From Day 0 to Day 308 Percentage of FEV1 will be measured using spirometry.
Time to first asthma exacerbation event From Day 0 to Day 308 Asthma exacerbation are defined as worsening of asthma which required use of systemic corticosteroids (≥3 days. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits.
Pharmacokinetics-AUC0-inf From Day 0 to Day 308 Area under the concentration-time curve from time 0 to infinity after 610 subcutaneous
Pharmacokinetics-AUC0-last From Day 0 to Day 308 Area under the concentration-time curve from time 0 to last time point after 610 subcutaneous
Number of asthma exacerbation From Day 0 to Day 308 Asthma exacerbation are defined as worsening of asthma which required use of systemic corticosteroids (≥3 days. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits.
Pharmacokinetics-Cmax From Day 0 to Day 308 Maximum observed concentration of 610
Pharmacokinetics-CL/F From Day 0 to Day 308 Apparent clearance of 610
Pharmacokinetics-t1/2 From Day 0 to Day 308 Terminal elimination half-life of 610
Pharmacodynamics-Eosinophils From Day 0 to Day 308 Absolute eosinophils account and change from baseline in percentage
Changes from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1) From Day 0 to Day 308 FEV1 is defined as the volume of air expelled from the lungs in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry.
Number of asthma exacerbations requiring hospitalization (including intubation and ICU admission) or emergency room visits (not conversion to hospitalization) From Day 0 to Day 308 Asthma exacerbations that are associated with a hospitalization or an emergency room visit.
Number of asthma exacerbations requiring hospitalization (including intubation and ICU admission) From Day 0 to Day 308 Asthma exacerbations that are associated with a hospitalization.
Change from baseline in Asthma Control Questionnaire score From Day 0 to Day 308 The ACQ has 7 questions- the first 5 items assess the most common asthma symptoms plus 6. short-acting bronchodilator use and 7. FEV1 (pre-bronchodilator use, % and % predicted use). Patients are asked to recall how their asthma has been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6= maximum impairment).
Change From Baseline in the St. George's Respiratory Questionnaire Total Score From Day 0 to Day 308 The St. George's Respiratory Questionnaire is an established instrument, comprising 50 questions, evaluating symptoms, activity, and impacts; to measure Quality of Life in participants with diseases of airway obstruction and to elicit the participant's opinion of his/her health.
Pharmacokinetics-Vz/F From Day 0 to Day 308 Apparent volume of distribution during terminal phase of 610
Trial Locations
- Locations (1)
Shanghai General Hospital
🇨🇳Shanghai, Shanghai, China